[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Acute Pancreatitis (AP) Market Insights, Epidemiology and Market Forecast-2028

July 2019 | 94 pages | ID: AEC9FE06558EN
DelveInsight

US$ 5,000.00 US$ 6,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 hours

DelveInsight’s ‘Acute Pancreatitis (AP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AP in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Pancreatitis (AP) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Acute Pancreatitis (AP) - Disease Understanding and Treatment Algorithm

The DelveInsight Acute Pancreatitis (AP) market report gives the thorough understanding of the Acute Pancreatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Pancreatitis in the US, Europe, and Japan.

Acute Pancreatitis Epidemiology

The Acute Pancreatitis (AP) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases, etiology based diagnosed incident cases, severity based diagnosed incident cases, gender based diagnosed incident cases and diagnosed incident cases of Recurrent AP) scenario of Acute Pancreatitis (AP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of diagnosed incident cases of Acute Pancreatitis (AP) in 7 MM was found to be 378,835, in the year 2017.

Acute Pancreatitis Drug Chapters

This segment of the Acute Pancreatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of supportive therapies) used for the management of AP. Intravenous fluids, analgesics, antibiotics and pancreatic enzymes which comprises the treatment pattern have been covered in the report.

Acute Pancreatitis Market Outlook

The Acute Pancreatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acute Pancreatitis in 7MM was found to be USD 549.7 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Acute Pancreatitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Pancreatitis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Acute Pancreatitis Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Acute Pancreatitis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Pancreatitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pancreatitis market
  • To understand the future market competition in the Acute Pancreatitis market.
1. REPORT INTRODUCTION

2. ACUTE PANCREATITIS MARKET OVERVIEW AT A GLANCE

2.1. Global Market Size of Acute Pancreatitis in 2017
2.2. Global Market Size of Acute Pancreatitis in 2028

3. DISEASE BACKGROUND AND OVERVIEW: ACUTE PANCREATITIS

3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Assumptions and Caveats
4.2. Acute Pancreatitis Geography Wise Incident Cases
  4.2.1. 7MM Diagnosed Incidence of Acute Pancreatitis (2017-2028)
  4.2.2. 7MM Diagnosed Incidence of AP by Etiology (2017-2028)
  4.2.3. 7MM Diagnosed Incidence of AP by Severity (2017-2028)
  4.2.4. 7MM Diagnosed Incidence of AP by Gender (2017-2028)
  4.2.5. 7MM Diagnosed Incidence of Recurrent AP Cases (2017-2028)
4.3. United States
  4.3.1. Diagnosed Incidence of Acute Pancreatitis in United States (2017-2028)
  4.3.2. Diagnosed Incidence of AP by Etiology in United States (2017-2028)
  4.3.3. Diagnosed Incidence of AP by Severity in United States (2017-2028)
  4.3.4. Diagnosed Incidence of AP by Gender in United States (2017-2028)
  4.3.5. Diagnosed Incidence of Recurrent AP Cases in United States (2017-2028)
4.4. EU-5
  4.4.1. Assumptions and Rationale
  4.4.2. Germany
    4.4.2.1. Diagnosed Incidence of Acute Pancreatitis in Germany (2017-2028)
    4.4.2.2. Diagnosed Incidence of AP by Etiology in Germany (2017-2028)
    4.4.2.3. Diagnosed Incidence of AP by Severity in Germany (2017-2028)
    4.4.2.4. Diagnosed Incidence of AP by Gender in Germany (2017-2028)
    4.4.2.5. Diagnosed Incidence of Recurrent AP Cases in Germany (2017-2028)
  4.4.3. Italy
    4.4.3.1. Diagnosed Incidence of Acute Pancreatitis in Italy (2017-2028)
    4.4.3.2. Diagnosed Incidence of AP by Etiology in Italy (2017-2028)
    4.4.3.3. Diagnosed Incidence of AP by Severity in Italy (2017-2028)
    4.4.3.4. Diagnosed Incidence of AP by Gender in Italy (2017-2028)
    4.4.3.5. Diagnosed Incidence of Recurrent AP Cases in Italy (2017-2028)
  4.4.4. Spain
    4.4.4.1. Diagnosed Incidence of Acute Pancreatitis in Spain (2017-2028)
    4.4.4.2. Diagnosed Incidence of AP by Etiology in Spain (2017-2028)
    4.4.4.3. Diagnosed Incidence of AP by Severity in Spain (2017-2028)
    4.4.4.4. Diagnosed Incidence of AP by Gender in Spain (2017-2028)
    4.4.4.5. Diagnosed Incidence of Recurrent AP Cases in Spain (2017-2028)
  4.4.5. France
    4.4.5.1. Diagnosed Incidence of Acute Pancreatitis in France (2017-2028)
    4.4.5.2. Diagnosed Incidence of AP by Etiology in France (2017-2028)
    4.4.5.3. Diagnosed Incidence of AP by Severity in France (2017-2028)
    4.4.5.4. Diagnosed Incidence of AP by Gender in France (2017-2028)
    4.4.5.5. Diagnosed Incidence of Recurrent AP Cases in France (2017-2028)
  4.4.6. United Kingdom
    4.4.6.1. Diagnosed Incidence of Acute Pancreatitis in UK (2017-2028)
    4.4.6.2. Diagnosed Incidence of AP by Etiology in UK (2017-2028)
    4.4.6.3. Diagnosed Incidence of AP by Severity in UK (2017-2028)
    4.4.6.4. Diagnosed Incidence of AP by Gender in UK (2017-2028)
    4.4.6.5. Diagnosed Incidence of Recurrent AP Cases in UK (2017-2028)
4.5. Japan
  4.5.1. Diagnosed Incidence of Acute Pancreatitis in Japan (2017-2028)
  4.5.2. Diagnosed Incidence of AP by Etiology in Japan (2017-2028)
  4.5.3. Diagnosed Incidence of AP by Severity in Japan (2017-2028)
  4.5.4. Diagnosed Incidence of AP by Gender in Japan (2017-2028)
  4.5.5. Diagnosed Incidence of Recurrent AP Cases in Japan (2017-2028)

5. TREATMENT ALGORITHM

5.1. United States
5.2. Europe
5.3. Japan

6. UNMET NEED

7. KEY EMERGING THERAPIES

7.1. Key Cross Competition
7.2. CM4620: CalciMedica
  7.2.1. Regulatory Milestones
  7.2.2. Clinical Development
  7.2.3. Product Profile
  7.2.4. Clinical Pipeline Activity
    7.2.4.1. Ongoing Trials Information
    7.2.4.2. Clinical Trial by Phase

8. ACUTE PANCREATITIS MARKET SIZE

8.1. Key Findings
8.2. Total 7MM Acute Pancreatitis Market Analysis
  8.2.1. Overview of Total Acute Pancreatitis Market (2017-2028)

9. 7MM ACUTE PANCREATITIS: COUNTRY-WISE MARKET ANALYSIS

9.1. United States Market Size
  9.1.1. Total Market Size
  9.1.2. Market Size by Therapies
9.2. Germany Market Size
  9.2.1. Total Market Size
  9.2.2. Market Size by Therapies
9.3. France Market Size
  9.3.1. Total Market Size
  9.3.2. Market Size by Therapies
9.4. United Kingdom Market Size
  9.4.1. Total Market Size
  9.4.2. Market Size by Therapies
9.5. Spain Market Size
  9.5.1. Total Market Size
  9.5.2. Market Size by Therapies
9.6. Italy Market Size
  9.6.1. Total Market Size
  9.6.2. Market Size by Therapies
9.7. Japan Market Size
  9.7.1. Total Market Size
  9.7.2. Market Size by Therapies

10. MARKET DRIVERS

11. MARKET BARRIERS

12. REPORT METHODOLOGY

12.1. Sources Used

13. DELVEINSIGHT CAPABILITIES

14. DISCLAIMER

15. ABOUT DELVEINSIGHT

LIST OF TABLES

Table 1 Diagnosed Incidence of Acute Pancreatitis in 7MM (2017-2028)
Table 2 Diagnosed Incidence of AP by Etiology in 7MM (2017-2028)
Table 3 Diagnosed Incidence of AP by Severity in 7MM (2017-2028)
Table 4 Diagnosed Incidence of AP by Gender in 7MM (2017-2028)
Table 5 Diagnosed Incidence of Recurrent AP Cases in 7MM (2017-2028)
Table 6 Diagnosed Incidence of Acute Pancreatitis in United States (2017-2028)
Table 7 Diagnosed Incidence of AP by Etiology in United States (2017-2028)
Table 8 Diagnosed Incidence of AP by Severity in United States (2017-2028)
Table 9 Diagnosed Incidence of AP by Gender in United States (2017-2028)
Table 10 Diagnosed Incidence of Recurrent AP Cases in United States (2017-2028)
Table 11 Diagnosed Incidence of Acute Pancreatitis in Germany (2017-2028)
Table 12 Diagnosed Incidence of AP by Etiology in Germany (2017-2028)
Table 13 Diagnosed Incidence of AP by Severity in Germany (2017-2028)
Table 14 Diagnosed Incidence of AP by Gender in Germany (2017-2028)
Table 15 Diagnosed Incidence of Recurrent AP Cases in Germany (2017-2028)
Table 16 Diagnosed Incidence of Acute Pancreatitis in France (2017-2028)
Table 17 Diagnosed Incidence of AP by Etiology in France (2017-2028)
Table 18 Diagnosed Incidence of AP by Severity in France (2017-2028)
Table 19 Diagnosed Incidence of AP by Gender in France (2017-2028)
Table 20 Diagnosed Incidence of Recurrent AP Cases in France (2017-2028)
Table 21 Diagnosed Incidence of Acute Pancreatitis in Italy (2017-2028)
Table 22 Diagnosed Incidence of AP by Etiology in Italy (2017-2028)
Table 23 Diagnosed Incidence of AP by Severity in Italy (2017-2028)
Table 24 Diagnosed Incidence of AP by Gender in Italy (2017-2028)
Table 25 Diagnosed Incidence of Recurrent AP Cases in Italy (2017-2028)
Table 26 Diagnosed Incidence of Acute Pancreatitis in Spain (2017-2028)
Table 27 Diagnosed Incidence of AP by Etiology in Spain (2017-2028)
Table 28 Diagnosed Incidence of AP by Severity in Spain (2017-2028)
Table 29 Diagnosed Incidence of AP by Gender in Spain (2017-2028)
Table 30 Diagnosed Incidence of Recurrent AP Cases in Spain (2017-2028)
Table 31 Diagnosed Incidence of Acute Pancreatitis in United Kingdom (2017-2028)
Table 32 Diagnosed Incidence of AP by Etiology in United Kingdom (2017-2028)
Table 33 Diagnosed Incidence of AP by Severity in United Kingdom (2017-2028)
Table 34 Diagnosed Incidence of AP by Gender in United Kingdom (2017-2028)
Table 35 Diagnosed Incidence of Recurrent AP Cases in United Kingdom (2017-2028)
Table 36 Diagnosed Incidence of Acute Pancreatitis in Japan (2017-2028)
Table 37 Diagnosed Incidence of AP by Etiology in Japan (2017-2028)
Table 38 Diagnosed Incidence of AP by Severity in Japan (2017-2028)
Table 39 Diagnosed Incidence of AP by Gender in Japan (2017-2028)
Table 40 Diagnosed Incidence of Recurrent AP Cases in Japan (2017-2028)
Table 41 CM4620, Clinical Trials by Recruitment status, 2019
Table 42 CM4620, Clinical Trials by Zone, 2019
Table 43 Total 7 Major Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 44 Region wise Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 45 United States Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 46 United States Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 47 Germany Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 48 Germany Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 49 France Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 50 France Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 51 United Kingdom Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 52 United Kingdom Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 53 Spain Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 54 Spain Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 55 Italy Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 56 Italy Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Table 57 Japan Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Table 58 Japan Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)

LIST OF FIGURES

Figure 1 Diagnosed Incidence of Acute Pancreatitis in 7MM (2017-2028)
Figure 2 Diagnosed Incidence of AP by Etiology in 7MM (2017-2028)
Figure 3 Diagnosed Incidence of AP by Severity in 7MM (2017-2028)
Figure 4 Diagnosed Incidence of AP by Gender in 7MM (2017-2028)
Figure 5 Diagnosed Incidence of Recurrent AP Cases in 7MM (2017-2028)
Figure 6 Diagnosed Incidence of Acute Pancreatitis in United States (2017-2028)
Figure 7 Diagnosed Incidence of AP by Etiology in United States (2017-2028)
Figure 8 Diagnosed Incidence of AP by Severity in United States (2017-2028)
Figure 9 Diagnosed Incidence of AP by Gender in United States (2017-2028)
Figure 10 Diagnosed Incidence of Recurrent AP Cases in United States (2017-2028)
Figure 11 Diagnosed Incidence of Acute Pancreatitis in Germany (2017-2028)
Figure 12 Diagnosed Incidence of AP by Etiology in Germany (2017-2028)
Figure 13 Diagnosed Incidence of AP by Severity in Germany (2017-2028)
Figure 14 Diagnosed Incidence of AP by Gender in Germany (2017-2028)
Figure 15 Diagnosed Incidence of Recurrent AP Cases in Germany (2017-2028)
Figure 16 Diagnosed Incidence of Acute Pancreatitis in France (2017-2028)
Figure 17 Diagnosed Incidence of AP by Etiology in France (2017-2028)
Figure 18 Diagnosed Incidence of AP by Severity in France (2017-2028)
Figure 19 Diagnosed Incidence of AP by Gender in France (2017-2028)
Figure 20 Diagnosed Incidence of Recurrent AP Cases in France (2017-2028)
Figure 21 Diagnosed Incidence of Acute Pancreatitis in Italy (2017-2028)
Figure 22 Diagnosed Incidence of AP by Etiology in Italy (2017-2028)
Figure 23 Diagnosed Incidence of AP by Severity in Italy (2017-2028)
Figure 24 Diagnosed Incidence of AP by Gender in Italy (2017-2028)
Figure 25 Diagnosed Incidence of Recurrent AP Cases in Italy (2017-2028)
Figure 26 Diagnosed Incidence of Acute Pancreatitis in Spain (2017-2028)
Figure 27 Diagnosed Incidence of AP by Etiology in Spain (2017-2028)
Figure 28 Diagnosed Incidence of AP by Severity in Spain (2017-2028)
Figure 29 Diagnosed Incidence of AP by Gender in Spain (2017-2028)
Figure 30 Diagnosed Incidence of Recurrent AP Cases in Spain (2017-2028)
Figure 31 Diagnosed Incidence of Acute Pancreatitis in United Kingdom (2017-2028)
Figure 32 Diagnosed Incidence of AP by Etiology in United Kingdom (2017-2028)
Figure 33 Diagnosed Incidence of AP by Severity in United Kingdom (2017-2028)
Figure 34 Diagnosed Incidence of AP by Gender in United Kingdom (2017-2028)
Figure 35 Diagnosed Incidence of Recurrent AP Cases in United Kingdom (2017-2028)
Figure 36 Diagnosed Incidence of Acute Pancreatitis in Japan (2017-2028)
Figure 37 Diagnosed Incidence of AP by Etiology in Japan (2017-2028)
Figure 38 Diagnosed Incidence of AP by Severity in Japan (2017-2028)
Figure 39 Diagnosed Incidence of AP by Gender in Japan (2017-2028)
Figure 40 Diagnosed Incidence of Recurrent AP Cases
Figure 41 CM4620, Clinical Trials by Recruitment status, 2019
Figure 42 CM4620, Clinical Trials by Zone, 2019
Figure 43 Total 7 Major Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 44 Region wise Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 45 United States Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 46 United States Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 47 Germany Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 48 Germany Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 49 France Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 50 France Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 51 United Kingdom Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 52 United Kingdom Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 53 Spain Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 54 Spain Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 55 Italy Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 56 Italy Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)
Figure 57 Japan Market Size of Acute Pancreatitis in USD, Million (2017-2028)
Figure 58 Japan Market Size of Acute Pancreatitis by Therapies in USD, Million (2017-2028)


KEY COMPANIES

CalciMedica, and others


More Publications